A Phase 2 interventional study of indacaterol/glycopyrrolate and indacaterol in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis. Completed at 40 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2012-11-30.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. indacaterol · Pulmonary Disease, Chronic Obstructive.
Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, this one is the 25th largest by enrollment, is one of 6 that started in 2007, is one of 8 in phase 2, and was the 9th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →None of the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →
indacaterol: first FDA approval 2011 (ARCAPTA NEOHALER), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 11 · Phase 3 26 · Phase 4 20
First in 2004; this study’s year is marked. 6 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 257 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 57 interventional studies. Of the 52 that completed or were terminated, 39 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 57 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
117 studies in Pulmonary Disease, Chronic Obstructive by Novartis: none open now, none under way, none of them phase 3. Of 110 finished, 94 (85%) have results posted.
Among the 117 studies in Pulmonary Disease, Chronic Obstructive by Novartis, this one is the 55th largest by enrollment of the 116 interventional ones that give a count, is one of 12 that started in 2007, is one of 21 in phase 2, and was the 14th registered.
Novartis’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 57 studies testing indacaterol in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 117 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An investigational inhalation product (QVA149) for the treatment of patients with Chronic Obstructive Pulmonary Disease (COPD) is being developed. This 14 day study will investigate the effect on heart rate and cardiovascular effects to ensure the product is safe.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two capsules indacaterol/glycopyrrolate 300/50 μg delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.
Drug: indacaterol/glycopyrrolate
One capsule indacaterol/glycopyrrolate 300/100 μg and one placebo capsule delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.
Drug: indacaterol/glycopyrrolate · Drug: placebo
One capsule indacaterol/glycopyrrolate 150/50 μg and one capsule 50 μg glycopyrrolate delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.
Drug: indacaterol/glycopyrrolate · Drug: glycopyrrolate
One capsule indacaterol 300 μg and one placebo capsule delivered via s single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.
Drug: indacaterol · Drug: placebo
Two placebo capsules delivered via a single dose dry powder inhaler in the morning for 14 days. The use of salbutamol/albuterol as rescue medication was permitted throughout the study.
Drug: placebo
Drug pages: Indacaterol · Glycopyrrolate
Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Also known as: QVA149
Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Also known as: QAB149
Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Change From Baseline in Mean 24 Hour Heart Rate at Day 14
Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 14. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least square means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min post salbutamol/albuterol + error.
Time frame: Baseline, Day 14
Change From Baseline in Mean 24 Hour Heart Rate at Day 1
Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 1. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least squares means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.
Time frame: Baseline, Day 1
Trough Forced Expiratory Volume in 1 Second (FEV1) at Day 1 and Day 14
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline is defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Least square means are based on the analysis of covariance: response variable=center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.
Time frame: Day 1, Day 14
Trough Forced Vital Capacity (FVC) at Day 1 and Day 14
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FVC was defined as the mean of two measurements at 23 hours 15 minutes and the 23 hours 45 minutes post dosing. Baseline was defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Analysis of covariance: FVC parameter = center + treatment + baseline FVC + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.
Time frame: Day 1 and Day 14
Change From Baseline in QTc (Fridericia's Formula) at Day 1
The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 1. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.
Time frame: Baseline, Day 1
Change From Baseline in QTc (Fridericia's Formula) at Day 7
The change from baseline in QTc at 30 minutes and 2 hours post dose on day 7. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.
Time frame: Baseline, Day 7
Change From Baseline in QTc (Fridericia's Formula) at Day 14
The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 14. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.
Time frame: Baseline, Day 14
| Milestone | Indacaterol/Glycopyrrolate 600 μg/100 μg | Indacaterol/Glycopyrrolate 300 μg/100 μg | Indacaterol/Glycopyrrolate 150 μg/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Started | 50 | 51 | 51 | 52 | 53 |
| Safety: received study drug | 49 | 51 | 51 | 51 | 53 |
| Completed | 44 | 48 | 46 | 48 | 49 |
| Not completed | 6 | 3 | 5 | 4 | 4 |
| Withdrew: Adverse event | 1 | 1 | 4 | 1 | 2 |
| Withdrew: Abnormal test procedure result(s) | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 2 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol deviation | 1 | 1 | 0 | 1 | 0 |
Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 14. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least square means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min post salbutamol/albuterol + error.
| beats per minute | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Mean 24 Hour Heart Rate at Day 14 | -0.113 ± 0.9967 | 0.787 ± 0.8975 | -0.230 ± 0.9567 | 0.240 ± 0.9373 | 0.170 ± 0.8760 |
Heart rate was assessed by Holter monitoring and was measured over a 24 hour period at day 1. Heart rate was defined as the average value over the 24 hour monitoring period. The baseline measurement was the average heart rate taken from the 24 hour Holter monitoring period performed at screening or the last 24-hour period before taking the first dose of study drug. Least squares means are based on the analysis of covariance: 24 hours mean heart rate = center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.
| beats per minute | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Mean 24 Hour Heart Rate at Day 1 | -2.877 ± 0.8790 | -2.770 ± 0.8244 | -0.547 ± 0.8208 | -1.849 ± 0.8211 | -0.329 ± 0.8181 |
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FEV1 was defined as the mean of two measurements at 23 hours 15 minutes and 23 hour 45 minutes post dosing. Baseline is defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Least square means are based on the analysis of covariance: response variable=center + treatment + baseline value + Forced Expiratory Volume in one second (FEV1) before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.
| Liters | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 1.59 ± 0.024 | 1.51 ± 0.023 | 1.50 ± 0.022 | 1.44 ± 0.023 | 1.27 ± 0.022 |
| Day 14 | 1.61 ± 0.027 | 1.52 ± 0.025 | 1.50 ± 0.026 | 1.46 ± 0.025 | 1.31 ± 0.024 |
Spirometry testing was performed in accordance with American Thoracic Society standards. Trough FVC was defined as the mean of two measurements at 23 hours 15 minutes and the 23 hours 45 minutes post dosing. Baseline was defined as the mean of the two values taken at 45 minutes and 15 minutes prior to dosing at day 1. Analysis of covariance: FVC parameter = center + treatment + baseline FVC + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min after inhalation of salbutamol/albuterol + error.
| Liters | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Day 1 | 3.151 ± 0.0437 | 3.029 ± 0.0421 | 3.000 ± 0.0403 | 2.924 ± 0.0419 | 2.634 ± 0.0402 |
| Day 14 (n=42, 45, 44, 48, 47) | 3.134 ± 0.0469 | 3.042 ± 0.0446 | 2.952 ± 0.0455 | 2.901 ± 0.0442 | 2.726 ± 0.0424 |
The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 1. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.
| milliseconds | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| 30 minutes | 1.6 ± 1.58 | 1.2 ± 1.48 | 1.4 ± 1.50 | 3.1 ± 1.47 | -1.6 ± 1.44 |
| 4 hours | 2.8 ± 1.67 | 0.5 ± 1.56 | 2.4 ± 1.58 | 1.1 ± 1.60 | -2.3 ± 1.52 |
| 23 hours 45 minutes | 2.7 ± 1.77 | -1.7 ± 1.66 | -0.1 ± 1.67 | -2.1 ± 1.71 | -2.3 ± 1.62 |
The change from baseline in QTc at 30 minutes and 2 hours post dose on day 7. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 min post inhalation of salbutamol/albuterol.
| milliseconds | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| 30 minutes | 4.1 ± 1.91 | -0.9 ± 1.74 | 0.5 ± 1.78 | -1.3 ± 1.79 | -2.2 ± 1.70 |
| 2 hours | 2.6 ± 2.17 | -1.2 ± 1.98 | 1.6 ± 2.02 | -1.6 ± 2.00 | -2.8 ± 1.94 |
The change from baseline in QTc at 30 minutes, 4 hours and 23 hours 45 minutes post dose on day 14. QT calculated (QTc) was calculated from the QT interval and RR (in seconds) using Fridericia's formula: QTc = QT / 3√ RR. Least square means are based on the analysis of covariance: response variable = center + treatment + baseline value + FEV1 before inhalation of salbutamol/albuterol + FEV1 30 minutes post inhalation of salbutamol/albuterol.
| milliseconds | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| 30 minutes | 2.4 ± 1.79 | -0.6 ± 1.64 | 1.6 ± 1.70 | -1.2 ± 1.69 | 0.2 ± 1.62 |
| 4 hours | 2.8 ± 1.90 | -0.1 ± 1.76 | 3.1 ± 1.85 | -2.6 ± 1.81 | -0.1 ± 1.73 |
| 23 hours 45 minutes | 0.5 ± 1.94 | -2.9 ± 1.81 | 0.4 ± 1.95 | -3.6 ± 1.88 | -1.6 ± 1.77 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Indacaterol/Glycopyrrolate 600/100 μg | — | 2/49 (4.1%) | 5/49 (10.2%) |
| Indacaterol/Glycopyrrolate 300/100 μg | — | 0/51 (0%) | 6/51 (11.8%) |
| Indacaterol/Glycopyrrolate 150/100 μg | — | 2/51 (3.9%) | 10/51 (19.6%) |
| Indacaterol 300 μg | — | 0/51 (0%) | 7/51 (13.7%) |
| Placebo | — | 1/53 (1.9%) | 4/53 (7.5%) |
| Event | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/49 | 0/51 | 0/51 | 0/51 | 0/53 |
| Blood potassium increasedInvestigations | 1/49 | 0/51 | 0/51 | 0/51 | 0/53 |
| AnaemiaBlood and lymphatic system disorders | 0/49 | 0/51 | 1/51 | 0/51 | 0/53 |
| Ventricular tachycardiaCardiac disorders | 0/49 | 0/51 | 1/51 | 0/51 | 0/53 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/49 | 0/51 | 0/51 | 0/51 | 1/53 |
| Event | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/49 | 2/51 | 5/51 | 1/51 | 1/53 |
| Dry mouthGastrointestinal disorders | 3/49 | 1/51 | 3/51 | 0/51 | 0/53 |
| CoughRespiratory, thoracic and mediastinal disorders | 3/49 | 2/51 | 3/51 | 2/51 | 1/53 |
| HeadacheNervous system disorders | 2/49 | 1/51 | 2/51 | 3/51 | 1/53 |
| HypertensionVascular disorders | 0/49 | 3/51 | 1/51 | 1/51 | 1/53 |
| Age Continuous(years) | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 65.7 ± 9.34 | 63.7 ± 8.94 | 60.9 ± 8.58 | 64.5 ± 9.75 | 64.3 ± 8.95 | 63.8 ± 9.19 |
| Sex: Female, Male(Participants) | Indacaterol/Glycopyrrolate 600/100 μg | Indacaterol/Glycopyrrolate 300/100 μg | Indacaterol/Glycopyrrolate 150/100 μg | Indacaterol 300 μg | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 11 | 10 | 15 | 10 | 14 | 60 |
| Male | 38 | 41 | 36 | 41 | 39 | 195 |
The record gives a start of Nov 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 4 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Indacaterol · Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →